Literature DB >> 7588090

A guide to the treatment of lower respiratory tract infections.

F Vogel1.   

Abstract

Acute bronchitis is usually a viral infection which, unless there is a special disposition, does not require antibiotic therapy. For the initial oral chemotherapy of bacterial infections of the lower respiratory tract (chronic bronchitis, pneumonia) the effective and well tolerated cephalosporins, macrolides and amoxicillin plus beta-lactamase-inhibitor are recommended. In complicated cases with severe underlying disease, longer history or frequent exacerbations, quinolones should be given if Gram-negative infections are suspected or if initial therapy with other substances has failed. If Legionella, Mycoplasma or Chlamydia spp., so-called 'atypical' pathogens, are involved, macrolide antibiotics are the therapy of first choice. Special attention should be given to the increase in resistance against cotrimoxazole (trimethoprim-sulfamethoxazole) and tetracyclines. In hospitals where primary pneumonias are treated preferentially by intravenous medication, therapy should be switched to oral antibiotics as soon as feasible (follow-up therapy). For severely ill patients with secondary pneumonia and underlying disease, second generation cephalosporins with aminoglycosides, or monotherapy with third generation cephalosporins are recommended. In very severe, high-risk cases, third generation cephalosporins, combinations with high-dosage quinolones or ureidopenicillins plus beta-lactamase-inhibitors are suitable. Future development in the antibiotic treatment of respiratory infections will follow the current trend of lower dosages, with the clear objective of shortening treatment periods and achieving earlier discharge from hospital.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588090     DOI: 10.2165/00003495-199550010-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  37 in total

1.  Initial antimicrobial treatment of hospital acquired pneumonia in adults: A conference report.

Authors:  L A Mandell; T J Marrie; M S Niederman
Journal:  Can J Infect Dis       Date:  1993-11

2.  Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.

Authors:  D Tremblay; A Dupront; C Ho; D Coussediere; B Lenfant
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

3.  Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens.

Authors:  N C James; K H Donn; J J Collins; I M Davis; T L Lloyd; R W Hart; J R Powell
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

4.  Proceedings of a conference: Clinical pharmacology and efficacy of cefixime. Sonoma, CA, March 20 and 21, 1987.

Authors: 
Journal:  Pediatr Infect Dis J       Date:  1987-10       Impact factor: 2.129

5.  Stomach as source of bacteria colonising respiratory tract during artificial ventilation.

Authors:  S T Atherton; D J White
Journal:  Lancet       Date:  1978-11-04       Impact factor: 79.321

Review 6.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 7.  Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections.

Authors:  R Kiani; D Johnson; B Nelson
Journal:  Am J Med       Date:  1988-09-16       Impact factor: 4.965

8.  Empirical antibiotic therapy for fever in neutropenic patients.

Authors:  G P Bodey
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

9.  Killing kinetics of cefuroxime axetil against Haemophilus influenzae in an in-vitro model simulating serum concentration profiles after oral administration.

Authors:  E Bingen; N Lambert-Zechovsky; C Doit; P Duvignaud; D Georges; P Mariani-Kurkdjian
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

10.  Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections.

Authors:  C J Schleupner; W C Anthony; J Tan; T M File; P Lifland; W Craig; B Vogelman
Journal:  Arch Intern Med       Date:  1988-02
View more
  4 in total

Review 1.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 2.  Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents?

Authors:  Friedrich Vogel
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

4.  Antibiotics in acute bronchitis: a meta-analysis.

Authors:  S Bent; S Saint; E Vittinghoff; D Grady
Journal:  Am J Med       Date:  1999-07       Impact factor: 4.965

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.